Clinical Trial

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with treatment-naïve NSCLC harboring L858R or del19 EGFR mutation who are suspected to have poor response upon single-agent TKI treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-03-15; most recent amendment 2025-02-20.
Trial Details
NCT Number NCT05281406
Lead Sponsor Goethe University
Conditions NSCLC Stage IIIB, NSCLC Stage IV
Enrollment 50 participants
Start Date 2021-11-12
Primary Completion 2025-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-02-21